Area of research
Infectious Diseases · Animal Science and Zoology
Research interest
Research interests include Virology, Biology, Immunology, Antibody, Vaccination, and Immune system.
The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response
SARS-CoV-2 inflammation durably imprints memory CD4 T cells
Multimodal single-cell datasets characterize antigen-specific CD8+ T cells across SARS-CoV-2 vaccination and infection
mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection
Optimized quantification of intra-host viral diversity in SARS-CoV-2 and influenza virus sequence data
Antibody Titers against Mpox Virus after Vaccination
Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational study
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study
Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines
Hybrid and vaccine‐induced immunity against <scp>SAR‐CoV</scp> ‐2 in <scp>MS</scp> patients on different disease‐modifying therapies
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following <scp>SARS</scp>–<scp>CoV</scp>‐2 Vaccination
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
Matrix lumican endocytosed by immune cells controls receptor ligand trafficking to promote TLR4 and restrict TLR9 in sepsis
High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
Mycobacterium tuberculosis Rv2700 Contributes to Cell Envelope Integrity and Virulence
Cytokinin Signaling in Mycobacterium tuberculosis
Proteasomal Control of Cytokinin Synthesis Protects Mycobacterium tuberculosis against Nitric Oxide
The Copper-Responsive RicR Regulon Contributes to Mycobacterium tuberculosis Virulence
The Pup-Proteasome System of Mycobacterium tuberculosis
Copper in Microbial Pathogenesis: Meddling with the Metal